Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: Preliminary analysis of the results of the IMPACT study

BJU International

Volumn 107, Issue 1, 2011, Pages 28-39

  Mitra, Anita V ^a   Bancroft, Elizabeth K ^a,b   Barbachano, Yolanda ^a,b   Page, Elizabeth C ^a   Foster, C S ^c   Jameson, C ^b   Mitchell, G ^d   Lindeman, G J ^e   Stapleton, A ^f   Suthers, G ^g   Evans, D G ^h   Cruger, D ⁱ   Blanco, I ^j   Mercer, C ^k   Kirk, J ^l   Maehle, L ^m   Hodgson, S ⁿ   Walker, L ^o   Izatt, L ^p   Douglas, F ^q   Tucker, K ^r   Dorkins, H ^s   Clowes, V ^t   Male, A ^u   Donaldson, A ^v   Brewer, C ^w   Doherty, R ^d   Bulman, B ^h   Osther, P J ^x   Salinas, M ^j   Eccles, D ^k   Axcrona, K ^m   Jobson, I ^q   Newcombe, B ^t   Cybulski, C ^x   Rubinstein, W S ^z   Buys, S ^aa   Townshend, S ^ab   Friedman, E ^ac   Domchek, S ^ad   Ramon Y Cajal, T ^ae   Spigelman, A ^af,ag   Teo, S H ^ah,ai   Nicolai, N ^aj   Aaronson, N ^ak   Ardern Jones, A ^b   Bangma, C ^al   Dearnaley, D ^a,b   Eyfjord, J ^am   Falconer, A ^an   Gronberg H ^ao   Hamdy, F ^ap   Johannsson, O ^aq   Khoo, V ^a   Kote Jarai, Z ^a   Lilja, H ^ar   Lubinski, J ^y   Melia, J ^a   Moynihan, C ^a   Peock, S ^as   Rennert, G ^at   Schroder F ^al   Sibley, P ^au   Suri, M ^av   Wilson, P ^aw   Bignon, Y J ^ax   Strom, S ^ay   Tischkowitz, M ^az   Liljegren, A ^ba   Ilencikova, D ^bb   Abele, A ^bc   Kyriacou, K ^bd   Van Asperen, C ^be   Kiemeney, L ^bf   Easton, D F ^as   Eeles, Rosalind A ^a,b   more..

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e ROYAL MELBOURNE HOSPITAL   (Australia)

^f REPATRIATION GENERAL HOSPITAL   (Australia)

^g UNIVERSITY OF ADELAIDE   (Australia)

^h ST MARY S HOSPITAL   (United Kingdom)

ⁱ LILLEBAELT HOSPITAL   (Denmark)

^j CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^k PRINCESS ANNE HOSPITAL   (United Kingdom)

^l WESTMEAD HOSPITAL   (Australia)

^m OSLO UNIVERSITY HOSPITAL   (Norway)

ⁿ ST GEORGE S HOSPITAL   (United Kingdom)

^o CHURCHILL HOSPITAL   (United Kingdom)

^p GUY S HOSPITAL   (United Kingdom)

^q NEWCASTLE UNIVERSITY   (United Kingdom)

^r PRINCE OF WALES HOSPITAL   (Australia)

^s EALING HOSPITAL NHS TRUST   (United Kingdom)

^t ADDENBROOKE S HOSPITAL   (United Kingdom)

^u UNIVERSITY COLLEGE LONDON   (United Kingdom)

^v ST MICHAEL'S HOSPITAL   (United Kingdom)

^w ROYAL DEVON AND EXETER HOSPITAL   (United Kingdom)

^x Fredericia and Kolding Hospital ^*  (Denmark)

^y POMERANIAN MEDICAL UNIVERSITY   (Poland)

^z NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^aa UNIVERSITY OF UTAH   (United States)

^ab KING EDWARD MEMORIAL HOSPITAL   (Australia)

^ac Chaim Shema Medical Center   (Israel)

^ad UNIVERSITY OF PENNSYLVANIA   (United States)

^ae HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^af Hunter Genetics   (Australia)

^ag UNIVERSITY OF NEW SOUTH WALES   (Australia)

^ah CANCER RESEARCH INITIATIVES FOUNDATION   (Malaysia)

^ai UNIVERSITY OF MALAYA   (Malaysia)

^aj NATIONAL CANCER INSTITUTE   (Italy)

^ak NETHERLANDS CANCER INSTITUTE   (Netherlands)

^al ERASMUS MEDICAL CENTER   (Netherlands)

^am UNIVERSITY OF ICELAND   (Iceland)

^an IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^ao UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^ap UNIVERSITY OF OXFORD   (United Kingdom)

^aq LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^ar MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^as UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^at CLALIT HEALTH SERVICES   (Israel)

^au Caernarfon   (United Kingdom)

^av NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^aw BioZenix   (United Kingdom)

^ax Jean Perrin Cancer Center   (France)

^ay UNIVERSITY OF TEXAS   (United States)

^az MCGILL UNIVERSITY   (Canada)

^ba KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^bb CANCER RESEARCH INSTITUTE   (Slovakia)

^bc RIGA STRADINS UNIVERSITY   (Latvia)

^bd CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^be LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^bf RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

BRCA1; BRCA2; genetic predisposition; prostate cancer; PSA

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER SCREENING; CONTROLLED STUDY; GENE MUTATION; GENETIC PREDISPOSITION; HUMAN; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

ADULT; AGED; EARLY DETECTION OF CANCER; EPIDEMIOLOGIC METHODS; GENES, BRCA1; GENES, BRCA2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MUTATION; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 78650657873     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.09648.x     Document Type: Article

References (54)

1. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst 1999; 91: 1310-6
2. Thompson D, Easton DF,. Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst 2002; 94: 1358-65 (Pubitemid 35154140)
3. Schröder FH, Bangma CH,. The European Randomized Study of Screening for Prostate Cancer (ERSPC). Br J Urol 1997; 79 (Suppl. 1): 68-71
4. Prorok PC, Andriole GL, Bresalier RS, et al.; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Project Team. Design of the the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21 (Suppl.): 273-309
5. Donovan J, Hamdy F, Neal D, et al. Prostate Testing for Cancer and Treatment (ProtecT) feasibility study. Health Technol Assess 2003; 7: 1-88
6. Andriole GL, Crawford ED, Grubb RL, III et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9
7. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
8. Smith RA, Cokkinides V, Brawley OW,. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009; 59: 27-41
9. McGregor M, Hanley JA, Boivin JF, McLean RG,. Screening for prostate cancer: estimating the magnitude of overdetection. CMAJ 1998; 159: 1368-72
10. Draisma G, De Koning HJ,. MISCAN: estimating lead-time and over-detection by simulation. BJU Int 2003; 92 (Suppl. 2): 106-11
11. Mitra A, Fisher C, Foster CS, et al. Prostate cancer in male BRCA1 and BRCA2 mutation carriers has a more aggressive phenotype. Br J Cancer 2008; 98: 502-7
12. Cuzick J, Fisher G, Kattan MW, et al. Long-term outcome among men with conservatively treated localized prostate cancer. Br J Cancer 2006; 95: 1186-94
13. McWhorter WP, Hernandez AD, Meikle AW, et al. A screening study of prostate cancer in high risk families. J Urol 1992; 148: 826-8
14. Narod SA, Dupont A, Cusan L, et al. The impact of family history on early detection of prostate cancer. Nat Med 1995; 1: 99-101
15. Matikainen MP, Schleutker J, Morsky P, Kallioniemi OP, Tammela TL,. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families. Clin Cancer Res 1999; 5: 1275-9
16. Mäkinen T, Tammela TL, Stenman UH, et al. Family history and prostate cancer screening with prostate-specific antigen. J Clin Oncol 2002; 20: 2658-63
17. Valeri A, Cormier L, Moineau MP, et al. Targeted screening for prostate cancer in high risk families: early onset is a significant risk factor for disease in first degree relatives. J Urol 2002; 168: 483-7
18. Catalona WJ, Antenor JA, Roehl KA, Moul JW,. Screening for prostate cancer in high risk populations. J Urol 2002; 168: 1980-3
19. Uzzo RG, Pinover WH, Horwitz EM, et al. Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digital rectal examination. Urology 2003; 61: 754-9
20. Horsburgh S, Matthew A, Bristow R, Trachtenberg J,. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic. Prostate 2005; 65: 124-9
21. Bunker CH, Patrick AL, Konety BR, et al. High prevalence of screening-detected prostate cancer among Afro-Caribbeans: the Tobago Prostate Cancer Survey. Cancer Epidemiol Biomarkers Prev 2002; 11: 726-9
22. Sartor O,. Early detection of prostate cancer in African-American men with an increased familial risk of disease. J La State Med Soc 1996; 148: 179-85
23. Kiemeney LA, Broeders MJ, Pelger M, et al. Screening for prostate cancer in Dutch hereditary prostate cancer families. Int J Cancer 2008; 122: 871-6
24. Tryggvadóttir L, Vidarsdóttir L, Thorgeirsson T, et al. Prostate cancer progression and survival in BRCA2 mutation carriers. J Natl Cancer Inst 2007; 99: 929-35
25. Narod SA, Neuhausen S, Vichodez G, et al. Rapid progression of prostate cancer in men with a BRCA2 mutation. Br J Cancer 2008; 99: 371-4
26. Lehrer S, Fodor F, Stock RG, et al. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer. Br J Cancer 1998; 78: 771-3
27. Nastiuk KL, Mansukhani M, Terry MB, et al. Common mutations in BRCA1 and BRCA2 do not contribute to early prostate cancer in Jewish men. Prostate 1999; 40: 172-7
28. Hubert A, Peretz T, Manor O, et al. The Jewish Ashkenazi founder mutation in the BRCA1/BRCA2 genes are not found at an increased frequency in Ashkenazi patients with prostate cancer. Am J Hum Genet 1999; 65: 921-4
29. Vazina A, Baniel J, Yaacobi Y, et al. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer in Israel. Br J Cancer 2000; 83: 463-6
30. Giusti RM, Rutter JL, Duray PH, et al. A twofold increase in BRCA mutation related prostate cancer among Ashkenazi Israelis is not associated with distinctive histopathology. J Med Genet 2003; 40: 787-92
31. Mitra AV, Bancroft EK, Eeles RA, IMPACT Steering Committee and Collaborators. A review of targeted screening for prostate cancer: introducing the IMPACT study. BJU Int 2007; 99: 1350-5
32. Berney DM, Fisher G, Kattan MW, et al. Major shifts in the treatment and prognosis of prostate cancer due to changes in pathological diagnosis and grading. BJU Int 2007; 100: 1240-4
33. National Institute of Health and Clinical Excellence. Prostate cancer: diagnosis and treatment guideline. 2008. Available at:. Accessed 1 October 2009
34. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106-31 (Pubitemid 46726449)
35. Green FL,. AJCC Cancer Staging Manual. Chicago: Springer, 2002
36. Lamerato LE, Marcus PM, Jacobsen G, Johnson CC,. Recruitment in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: the First Phase of Recruitment at Henry Ford Health System. Cancer Epidemiol Biomarkers Prev 2008; 17: 827-33
37. Melia J, Dearnaley D, Moss S, et al. The feasibility and results of a population-based approach to evaluating prostate-specific antigen screening for prostate cancer in men with a raised familial risk. Br J Cancer 2006; 94: 499-506
38. Roobol MJ, Schröder FH, Kranse R,. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). Prostate 2006; 66: 604-12
39. Liede A, Metcalfe K, Hanna D, et al. Evaluation of the needs of male carriers of mutations in BRCA1 or BRCA2 who have undergone genetic counseling. Am J Hum Genet 2000; 67: 1494-504
40. Brooks L, Lennard F, Shenton A, et al. BRCA1/2 predictive testing: a study of uptake in two centers. Eur J Hum Genet 2004; 12: 654-62
41. Evans DGR, Binchy A, Shenton A, Hopwood P, Craufurd D,. Comparison of proactive and usual approaches to offering predictive testing for BRCA1/2 mutations in unaffected relatives. Clin Genet 2009; 75: 124-32
42. McAllister MF, Evans DG, Ormiston W, Daly P,. Men in breast cancer families: a preliminary qualitative study of awareness and experience. J Med Genet 1998; 35: 739-44
43. Meiser B, Cowan R, Costello A, Giles GG, Lindeman GJ, Gaff CL,. Prostate cancer screening in men with a family history of prostate cancer: the role of partners in influencing men's screening uptake. Urology 2007; 70: 738-42
44. Roobol MJ, Zappa M, Maattanen L, Ciatto S,. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC). Prostate 2007; 67: 439-46
45. Postma R, Schröder FH, van Leenders GJ, et al. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)-Section Rotterdam. A comparison of two rounds of screening. Eur Urol 2007; 52: 89-97 (Pubitemid 46803013)
46. Khan MA, Partin AW, Rittenhouse HG, et al. Evaluation of pro-prostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0-10.0 ng/mL. J Urol 2003; 170: 723-6
47. Billis A, Meirelles L, Freitas LL, Magna LA, Ferreira U,. Does the type of prostatic atrophy influence the association of extent of atrophy in needle biopsies and serum prostate-specific antigen levels? Urology 2009; 74: 1111-5
48. Verhamme KM, Dieleman JP, Bleumink GS, et al. Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care-the Triumph project. Eur Urol 2002; 42: 323-8
49. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860-4
50. Schröder FH, Carter HB, Wolters T, et al. Early detection of prostate cancer in 2007. Part 1: PSA and PSA kinetics. Eur Urol 2008; 53: 468-77
51. Schröder FH, Roobol MJ, Van Leenders GJLH, Bangma CH,. Should men age 55-74 presenting with PSA <3.0 ng/ml be biopsied to diagnose prostate cancer? Eur Urol Suppl 2007; 6: 222
52. Cancer Research UK 2009. Available at:. Accessed 1 October 2009
53. Australia's Health 2004. Available at:. Accessed 1 October 2009
54. Howard K, Barratt A, Mann GJ, Patel MI,. A model of prostate-specific antigen screening outcomes for low to High Risk Men. Arch Intern Med 2009; 169 (17): 1603-10